PriceTargets.com logo

F-star Therapeutics - FSTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.12 As of 03/9/2023 01:00 AM ET
+0 (0.00%)
Get New F-star Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FSTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FSTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for F-star Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.12.

This chart shows the closing price for FSTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in F-star Therapeutics. This rating has held steady since June 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/15/2022HC WainwrightDowngradeBuy ➝ Neutral
6/23/2022Leerink PartnersDowngradeOutperform ➝ Market Perform
6/23/2022LaidlawDowngradeBuy ➝ Hold
6/23/2022LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
6/23/2022William BlairDowngradeOutperform ➝ Market Perform
5/17/2022HC WainwrightInitiated CoverageBuy$35.00
3/17/2022HC WainwrightReiterated RatingBuy$35.00
11/18/2021LADENBURG THALM/SH SHLower TargetBuy$27.00 ➝ $15.00
11/12/2021OppenheimerBoost TargetOutperform$30.00 ➝ $33.00
10/22/2021William BlairReiterated RatingBuy
9/21/2021HC WainwrightReiterated RatingBuy$35.00
8/17/2021Leerink PartnersLower TargetOutperform$39.00 ➝ $35.00
7/8/2021Leerink PartnersInitiated CoverageOutperform$39.00
6/8/2021B. RileyInitiated CoverageBuy$28.00
5/18/2021HC WainwrightInitiated CoverageBuy$35.00
4/15/2021OppenheimerInitiated CoverageOutperform$30.00
4/8/2021William BlairInitiated CoverageOutperform
3/24/2021LaidlawInitiated CoverageBuy$32.00
3/1/2021HC WainwrightInitiated CoverageBuy$35.00
12/2/2020LADENBURG THALM/SH SHInitiated CoverageBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
F-star Therapeutics logo
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $7.12
Low: $7.12
High: $7.12

50 Day Range

MA: $6.19
Low: $4.42
High: $7.12

52 Week Range

Now: $7.12
Low: $2.07
High: $7.12

Volume

N/A

Average Volume

709,213 shs

Market Capitalization

$156.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of F-star Therapeutics?

The following Wall Street sell-side analysts have issued reports on F-star Therapeutics in the last twelve months:
View the latest analyst ratings for FSTX.

What is the current price target for F-star Therapeutics?

0 Wall Street analysts have set twelve-month price targets for F-star Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for F-star Therapeutics in the next year.
View the latest price targets for FSTX.

What is the current consensus analyst rating for F-star Therapeutics?

F-star Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FSTX.

What other companies compete with F-star Therapeutics?

Other companies that are similar to F-star Therapeutics include Pharming Group, Mineralys Therapeutics, Terns Pharmaceuticals, ORIC Pharmaceuticals and Savara. Learn More about companies similar to F-star Therapeutics.

How do I contact F-star Therapeutics' investor relations team?

F-star Therapeutics' physical mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company's listed phone number is 441223497400 and its investor relations email address is [email protected]. The official website for F-star Therapeutics is www.f-star.com. Learn More about contacing F-star Therapeutics investor relations.